<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04963257</url>
  </required_header>
  <id_info>
    <org_study_id>2019-234</org_study_id>
    <nct_id>NCT04963257</nct_id>
  </id_info>
  <brief_title>Sertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder</brief_title>
  <official_title>A Randomized Controlled Trial of Sertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To verify that sertraline combined with fluvoxamine is superior to sertraline combined with&#xD;
      aripiprazole&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To verify that sertraline combined with fluvoxamine is superior to sertraline combined with&#xD;
      aripiprazole, and to observe the indicators of improving patients' cognitive function and&#xD;
      adverse drug reactions, so as to provide evidence-based evidence for supplementing the&#xD;
      treatment guidelines for obsessive-compulsive disorder&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Y-BOCS score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Treatment effectiveness was defined as a reduction of ≥35% in Y-BOCS score compared to baseline(12 weeks). Treatment recovery: Y-BOCS score below 8 (12 weeks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Y-BOCS score reduction from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Treatment effectiveness was defined as a reduction of ≥35% in Y-BOCS score compared to baseline(12 weeks).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>OCD</condition>
  <arm_group>
    <arm_group_label>sertraline combined with fluvoxamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sertraline combined with fluvoxamine treatment group: Gradually add the drug to the treatment dose, and monitor the symptom change, scale score, blood drug concentration and other indicators</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sertraline combined with aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sertraline combined with aripiprazole treatment group:Gradually add the drug to the treatment dose, and monitor the symptom change, scale score, blood drug concentration and other indicators</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline fluvoxamine</intervention_name>
    <description>the initial dose of sertraline was given 50mg/d and the initial dose of fluvoxamine was 50mg/d, and the target dose of sertraline was gradually increased to 200mg/ d and the target dose of fluvoxamine was 200-300mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions</description>
    <arm_group_label>sertraline combined with fluvoxamine</arm_group_label>
    <other_name>fluvoxamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline</intervention_name>
    <description>The initial dose of sertraline was 50mg/d and the initial dose of aripiprazole was 5mg/d. The target dose of sertraline was 200mg/ d and the target dose of aripiprazole was 5-20mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions</description>
    <arm_group_label>sertraline combined with aripiprazole</arm_group_label>
    <other_name>aripiprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The Diagnostic criteria of OCD in the Diagnostic and Statistical Manual of Mental&#xD;
             Disorders 5th edition (DSM-V), as well as the definition of refractory OCD, are as&#xD;
             follows: failure to respond to oral treatment with at least two effective doses of&#xD;
             antidepressants, including: Fluoxetine (≥20mg/ d), fluvoxamine (≥200mg/d), sertraline&#xD;
             (≥150mg/d), and paroxetine (≥ 40mg/d) were all treated for at least 12 weeks. The&#xD;
             Yale-Brown compulsive scale (Y-BOCS) score decreased by &lt; 35%.&#xD;
&#xD;
          -  The total score of Yale- Brown compulsion scale (Y-BOCS) ≥16 points. (3)age 12 ~ 45&#xD;
             years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion of severe organic brain disease;&#xD;
&#xD;
          -  Severe physical illness;&#xD;
&#xD;
          -  Other mental disorders such as tics, disruptive disorders, eating disorders and autism&#xD;
             spectrum disorders;&#xD;
&#xD;
          -  Pediatric streptococcal infection causedby autoimmune neuropsychiatric disease&#xD;
             (PANDAS);&#xD;
&#xD;
          -  Alcohol and drug dependence; Angle-closure glaucoma;&#xD;
&#xD;
          -  Suicidal tendencies;&#xD;
&#xD;
          -  Previous history of drug allergies related to research;&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zheng Lin, Doctor</last_name>
    <phone>13757118261</phone>
    <email>linzzr@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fourth Affiliated Hospital of Zhejiang University Medical College</name>
      <address>
        <city>Yiwu</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yunrong lu, doctor</last_name>
      <phone>13757118257</phone>
      <email>13757118257@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sertraline</keyword>
  <keyword>OCD</keyword>
  <keyword>fluvoxamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

